Cost-effectiveness of interferon-α₂ as adjuvant therapy in malignant melanoma

Author： Lafuma Antoine Grob Jean Jacques

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.3, 2003-03, pp. : 343-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

By Sabel Michael S. Sondak Vernon K.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 1, 2004-01 ,pp. : 61-68

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Adjuvant interferon- -2a of no benefit in malignant melanoma

Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Interferon-α-2b: Primary cutaneous malignant melanoma (first report) in patients with malignant melanoma: 3 case reports

Reactions Weekly, Vol. 1, Iss. 1260, 2009-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Cost Effectiveness and Cost Utility of Adjuvant Interferon in Cutaneous Melanoma: A Review

By Crott R.

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 569-580

Adis International

Access to resources Recommend Favorite

Interferon-α of variable value in melanoma

Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite